DK4288426T3 - Quinoxalinderivater og anvendelser deraf - Google Patents

Quinoxalinderivater og anvendelser deraf

Info

Publication number
DK4288426T3
DK4288426T3 DK22705676.9T DK22705676T DK4288426T3 DK 4288426 T3 DK4288426 T3 DK 4288426T3 DK 22705676 T DK22705676 T DK 22705676T DK 4288426 T3 DK4288426 T3 DK 4288426T3
Authority
DK
Denmark
Prior art keywords
quinoxaline derivatives
quinoxaline
derivatives
Prior art date
Application number
DK22705676.9T
Other languages
Danish (da)
English (en)
Inventor
Matthew C Lucas
Fernando Padilla
Original Assignee
Black Diamond Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Black Diamond Therapeutics Inc filed Critical Black Diamond Therapeutics Inc
Application granted granted Critical
Publication of DK4288426T3 publication Critical patent/DK4288426T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Luminescent Compositions (AREA)
DK22705676.9T 2021-02-05 2022-02-04 Quinoxalinderivater og anvendelser deraf DK4288426T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163146312P 2021-02-05 2021-02-05
US202163223255P 2021-07-19 2021-07-19
US202163242260P 2021-09-09 2021-09-09
PCT/US2022/015353 WO2022170122A1 (en) 2021-02-05 2022-02-04 Quinoxaline derivatives and uses thereof

Publications (1)

Publication Number Publication Date
DK4288426T3 true DK4288426T3 (da) 2026-04-20

Family

ID=80446119

Family Applications (1)

Application Number Title Priority Date Filing Date
DK22705676.9T DK4288426T3 (da) 2021-02-05 2022-02-04 Quinoxalinderivater og anvendelser deraf

Country Status (10)

Country Link
US (1) US20240368181A1 (cg-RX-API-DMAC7.html)
EP (2) EP4759369A3 (cg-RX-API-DMAC7.html)
JP (1) JP2024512874A (cg-RX-API-DMAC7.html)
KR (1) KR20240006494A (cg-RX-API-DMAC7.html)
AU (1) AU2022215616A1 (cg-RX-API-DMAC7.html)
CA (1) CA3207475A1 (cg-RX-API-DMAC7.html)
DK (1) DK4288426T3 (cg-RX-API-DMAC7.html)
FI (1) FI4288426T3 (cg-RX-API-DMAC7.html)
MX (1) MX2023009166A (cg-RX-API-DMAC7.html)
WO (1) WO2022170122A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023247670A1 (en) * 2022-06-24 2023-12-28 F. Hoffmann-La Roche Ag New heterocyclic-carbonyl-cyclic compounds as magl inhibitors
CA3266687A1 (en) * 2022-09-07 2024-03-14 Eli Lilly And Company PYRAZOLO[1,5-A]PYRIDINE AND IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS FGFR3 INHIBITORS FOR CANCER TREATMENT
WO2025117550A1 (en) * 2023-12-01 2025-06-05 Black Diamond Therapeutics, Inc. Solid state forms of a quinoxaline derivative useful in the treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
WO2005007099A2 (en) * 2003-07-10 2005-01-27 Imclone Systems Incorporated Pkb inhibitors as anti-tumor agents
EP2806874B1 (en) * 2012-01-25 2017-11-15 Neupharma, Inc. Quinoxaline-oxy-phenyl derivatives as kinase inhibitors
JO3512B1 (ar) * 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز

Also Published As

Publication number Publication date
WO2022170122A1 (en) 2022-08-11
US20240368181A1 (en) 2024-11-07
JP2024512874A (ja) 2024-03-21
EP4288426A1 (en) 2023-12-13
AU2022215616A1 (en) 2023-09-07
FI4288426T3 (fi) 2026-04-21
EP4288426B8 (en) 2026-03-11
KR20240006494A (ko) 2024-01-15
EP4759369A3 (en) 2026-08-19
EP4759369A2 (en) 2026-06-17
EP4288426B1 (en) 2026-02-04
CA3207475A1 (en) 2022-08-11
MX2023009166A (es) 2023-11-07

Similar Documents

Publication Publication Date Title
DK3917616T3 (da) Heterocykliske forbindelser og anvendelse deraf
DK4461734T3 (da) Tyk2-hæmmere og anvendelser deraf
IL312845A (en) Exatecan derivatives, linker-payloads, and conjugates and thereof
DK4161935T3 (da) Brm-målrettende forbindelser og tilhørende anvendelsesmetoder
DK4196479T3 (da) Substituerede pyridotriazinforbindelser og anvendelser deraf
EP4294790A4 (en) SMARCA DEGRADING AGENTS AND RELATED USES
IL312330A (en) Tyk2 degraders and uses thereof
EP3820467A4 (en) ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES
IL310931A (en) 6-aza-quinoline derivatives and related uses
DK3922266T3 (da) Toll-like-receptor-7- eller -8-agonist-kolesterolkompleks og anvendelse deraf
DK4034535T3 (da) Aza-quinolinforbindelser og anvendelser deraf
DK3919498T6 (da) Pyrrolopyrimidinderivat og anvendelse deraf
EP4504190A4 (en) OXADIAZOLE HDAC6 INHIBITORS AND THEIR USES
DK3983387T3 (da) Sulfonylurinstofderivater og anvendelser deraf
EP4198040C0 (de) Pt-dpephos-iod-komplex und pt-dpephos-brom-komplex
EP4244205A4 (en) IRE1ALPHA INHIBITORS AND THEIR USES
EP4487731C0 (en) PULL ROD AND SUITCASE
IL312263A (en) Lurbinectedin and atezolizumab combinations
EP4384500C0 (en) PHENOXY-ACETYL-THIOUREIDO-BENZENESULFONAMIDE DERIVATIVES AND THEIR USES
KR102648314B9 (ko) 벤즈이미다졸 유도체 화합물 및 이의 용도
IL311782A (en) Transposases and uses thereof
PL4198001T3 (pl) Kompleks Pt-bifenyl-jod i kompleks Pt-bifenyl-brom
EP4037106C0 (de) Steckverbindung und steckverbindungsanordnung
IL307377A (en) Heterocyclic compounds and their use
EP4197995C0 (de) Pt-xanthen-iod-komplex und pt-xanthen-brom-komplex